Despite recent development of various new approaches to therapy, breast cancer remains the second leading cause of cancer death in women. Treatment with anti-angiogenic drugs combined with conventional cytotoxic drugs or immunotherapy is a promising means of treating aggressive cancer. Anti-angiogenic drugs are thought to temporarily normalize abnormal vasculature and paradoxically increase blood flow and hence delivery of drug and effector immune cells to tumors. However, a substantial proportion of patients do not respond to this combination therapy and it is unclear whether the failure is due to failure of the anti-angiogenic to normalize the vasculature or failure of the cytotoxic drugs or immune cells to kill cancer cells. It is therefore necessary to assess both blood flow and cell death to elucidate the mechanism and to optimize the combination treatments. In this proposal we investigate a single MRI acquisition and analysis that will allow assessment of both. Dynamic contrast enhanced (DCE) MRI has been widely used as an important part of most clinical MRI exams for diagnosis of cancer, and it holds high potential as a single MRI method to estimate both perfusion parameters (such as, flow, F, vascular volume fraction, vp, and vascular permeability-surface area product, PS) and cellular parameters (such as, interstitial volume fraction, ve, and intracellular water life time, ?i). Recently, we developed a novel data acquisition method, namely active contrast encoding (ACE)-MRI, which measures dynamic data together with pre-contrast T1 and B1 that are critical for measurement of perfusion and cellular parameters. ACE-MRI is also implemented with a fast 3D imaging method to acquire high-spatial and high- temporal resolution data using a 3D golden-angle ultra-short echo-time (UTE) sequence and an image reconstruction method to combine both compressed sensing and parallel imaging, also known as GRASP (Golden-angle RAdial Sparsity and Parallel). In this study, we plan to further develop ACE-MRI for accurate estimation of contrast agent concentration in vascular plasma and tissue using a direct blood sampling method (Aim 1), and to assess the association of ?i with tumor metabolic rate and treatment response in comparison with 18F-FDG-PET and pathology (Aim 2). Overall, the ACE-MRI parameters will be used to assess treatment response and metastatic potential (Aim 3). This study will be conducted with murine and human breast cancer models at a 7T small animal MRI scanner. However, the methods developed in this study can be easily translated to clinical applications as it is used on a UTE sequence readily available on most clinical scanners.
Assessment of cancer treatment requires an effective non-invasive method of measuring both the vascular and cellular changes induced by the therapies. Our underlying hypotheses is that a single dynamic contrast enhanced MRI measurement using the Active Contrast Encoding MRI method can provide a fast and quantitative means to assess both anti-angiogenic and cytotoxic responses to the therapy. The research in this proposal will establish an innovative method of assessing chemotherapy that will significantly improve drug discovery and patient management in a variety of cancers including breast cancer.
|Wake, Nicole; Chandarana, Hersh; Rusinek, Henry et al. (2018) Accuracy and precision of quantitative DCE-MRI parameters: How should one estimate contrast concentration? Magn Reson Imaging 52:16-23|
|Winters, Kerryanne V; Reynaud, Olivier; Novikov, Dmitry S et al. (2018) Quantifying myofiber integrity using diffusion MRI and random permeable barrier modeling in skeletal muscle growth and Duchenne muscular dystrophy model in mice. Magn Reson Med 80:2094-2108|
|Heacock, Laura; Lewin, Alana A; Gao, Yiming et al. (2018) Feasibility analysis of early temporal kinetics as a surrogate marker for breast tumor type, grade, and aggressiveness. J Magn Reson Imaging 47:1692-1700|
|Zhang, Jin; Winters, Kerryanne; Reynaud, Olivier et al. (2017) Simultaneous measurement of T1 /B1 and pharmacokinetic model parameters using active contrast encoding (ACE)-MRI. NMR Biomed 30:|
|Benkert, Thomas; Block, Kai Tobias; Heller, Samantha et al. (2017) Comprehensive Dynamic Contrast-Enhanced 3D Magnetic Resonance Imaging of the Breast With Fat/Water Separation and High Spatiotemporal Resolution Using Radial Sampling, Compressed Sensing, and Parallel Imaging. Invest Radiol 52:583-589|
|Kim, Sungheon Gene; Freed, Melanie; Leite, Ana Paula Klautau et al. (2017) Separation of benign and malignant breast lesions using dynamic contrast enhanced MRI in a biopsy cohort. J Magn Reson Imaging 45:1385-1393|
|Kim, Sungheon Gene; Friedman, Kent; Patel, Sohil et al. (2016) Potential Role of PET/MRI for Imaging Metastatic Lymph Nodes in Head and Neck Cancer. AJR Am J Roentgenol 207:248-56|
|Freed, Melanie; Storey, Pippa; Lewin, Alana Amarosa et al. (2016) Evaluation of Breast Lipid Composition in Patients with Benign Tissue and Cancer by Using Multiple Gradient-Echo MR Imaging. Radiology 281:43-53|
|Margolis, Nathaniel E; Moy, Linda; Sigmund, Eric E et al. (2016) Assessment of Aggressiveness of Breast Cancer Using Simultaneous 18F-FDG-PET and DCE-MRI: Preliminary Observation. Clin Nucl Med 41:e355-61|
|Lewin, Alana A; Kim, Sungheon Gene; Babb, James S et al. (2016) Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis. Acad Radiol 23:358-67|
Showing the most recent 10 out of 17 publications